Invesco Ltd. : Form 8.3 - Booker Group PLC FORM 8.3

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
101
Invesco Ltd. : Form 8.3 - Booker Group PLC

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Full name of discloser:   Invesco Ltd.
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):      The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.    
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:      Use a separate form for each offeror/offeree     Booker Group Plc.
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:    
(e) Date position held/dealing undertaken:      For an opening position disclosure, state the latest practicable date prior to the disclosure   27 November 2017
(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?      If it is a cash offer or possible cash offer, state "N/A"   Yes: Tesco Plc.  

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

  1. Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:     GB00B01TND91 1p Ordinary Shares
      Interests Short positions
  Number   % Number   %
(1) Relevant securities owned and/or controlled:   28,871,348   1.61 %      
(2) Cash-settled derivatives:                
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:              
       TOTAL:   28,871,348   1.61 %      

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)        Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:    
Details, including nature of the rights concerned and relevant percentages:    

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

  1. Purchases and sales
Class of relevant security   Purchase/sale     Number of securities   Price per unit
Ordinary     Purchase   24,126   2.16 GBP

 (b)       Cash-settled derivative transactions

Class of relevant security   Product description e.g. CFD   Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short  position   Number of reference securities   Price per unit
                   

(c)        Stock-settled derivative transactions (including options)

(i)         Writing, selling, purchasing or varying

Class of relevant security   Product description e.g. call option   Writing, purchasing, selling, varying etc.   Number of securities to which option relates   Exercise price per unit   Type e.g. American, European etc.   Expiry date   Option money paid/ received per unit
                             

(ii)        Exercise

Class of relevant security   Product description e.g. call option   Exercising/ exercised against   Number of securities   Exercise price per unit
                   

(d)        Other dealings (including subscribing for new securities)

Class of relevant security   Nature of dealing e.g. subscription, conversion   Details   Price per unit (if applicable)
               

4.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None  

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?   NO
Date of disclosure:   28 November 2017
Contact name:   Cathy Dixon
Telephone number:   01491 416 191

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Textile Recycling Industry Expected to Hit $7.26 Billion Catalyst

Updated Category News Views 171

Understanding the Textile Recycling Market Growth The global textile recycling market is experiencing significant transformation fueled by a growing emphasis on sustainability and environmental awareness. With a projected value reaching approximately $7.26 billion, and an expected annual growth rate of 4.9%, the industry reflects changing consumer preferences and global...

Continue Reading
Mobile Infrastructure Secures $100M for Growth and Diversification

Updated Category News Views 168

Mobile Infrastructure Corporation Closes Major Financing Round Mobile Infrastructure Corporation (NASDAQ: BEEP) has successfully completed a significant $100 million Asset-Backed Securitization (ABS) focused on enhancing its financial structure and opening avenues for future growth. This landmark achievement is a testament to the forward-thinking strategies and the robust...

Continue Reading
Navigating the Kiosk Market: Trends and Future Growth Insights

Updated Category News Views 198

Global Kiosk Market Overview As we delve into the dynamic landscape of the kiosk market, projections indicate an impressive growth trajectory. The global kiosk market is set to expand significantly, with expectations to reach a remarkable USD 62.2 billion by the end of the forecast period. The anticipated compound annual growth rate (CAGR) of 12.74% from 2024 to 2031...

Continue Reading
Exploring Wallbridge Mining's New Phase 2 Drilling Initiative

Updated Category News Views 121

Wallbridge Mining Launches Phase 2 Drilling at Martiniere Wallbridge Mining Company Limited (TSX: WM, OTCQB: WLBMF) is excited to announce that it has commenced its second phase of drilling at the fully owned Martiniere gold project. This new drilling campaign aims to build on the positive results from its Phase 1 drilling campaign. Continuing Exploration Efforts The...

Continue Reading
Spirovant Sciences Advances Gene Therapy for Cystic Fibrosis

Updated Category News Views 117

Spirovant Sciences Launches Groundbreaking Gene Therapy Trial Spirovant Sciences, a pioneering clinical-stage gene therapy company, has taken a significant step forward in the battle against cystic fibrosis with the administration of the first dose in their SAAVe Phase 1/2 clinical trial of SP-101 combined with a unique augmenter. The Innovative SP-101 Treatment SP-101 is...

Continue Reading